

Conference Feedback

Participant Information

Name: _____
 Title: _____
 Company: _____
 Telephone: _____

We have strived to ensure that every session at this conference was informative and compelling. We value your opinion and appreciate your cooperation.

Please return this survey to the conference registration desk or fax to: (617) 621-1620.

Please evaluate speakers' style and content on a scale from 1 (poor) - 5 (excellent)

Tuesday, May 11	Presentation		Additional Comments
	Style	Content	
Michael Rosenblatt, MD <i>Perspective—The Impact of the Evolving Post-Approval Landscape</i>	_____	_____	_____ _____ _____
Gerald Dal Pan, MD, MHS <i>Evolving Role and Expectations for REMS and Safety Programs</i>	_____	_____	_____ _____ _____
Stella Blackburn, MA, MSc, FRCP(Ed), FFPM <i>European Updates to Risk Management</i>	_____	_____	_____ _____ _____
Eleanor Segal, MD <i>Case Study: Using a Registry for REMS and PASS Requirements</i>	_____	_____	_____ _____ _____
Sharon-Lise Normand, PhD <i>Designing Safety Studies: Interventional vs Observational</i>	_____	_____	_____ _____ _____
Richard E. Kuntz, MD <i>Challenges of Device Tracking and Adverse Event Reporting</i>	_____	_____	_____ _____ _____
Marc Berthiaume, MD <i>Integrating Risk Management Planning into the Regulatory Decision-Making Process</i>	_____	_____	_____ _____ _____
Stella Blackburn, MA, MSc, FRCP(Ed), FFPM Nancy Dreyer, MPH, PhD Michael Ibara, PharmD <i>New Innovations in Safety</i>	_____	_____	_____ _____ _____ _____
Anne Marie Conway <i>Case Study: Using a Registry to Evaluate Clinical Outcomes and Monitor Safety</i>	_____	_____	_____ _____ _____

Wednesday, May 12

Style Content Additional Comments

Patrick Conway, MD, MSc <i>Keynote—ARRA and Comparative Effectiveness Research in the New U.S. Healthcare System</i>	_____	_____	_____
Steve Romano, MD <i>Planning Across the Product Lifecycle: Addressing New Challenges for Post-Approval Data Requirements</i>	_____	_____	_____
Barry M. Straube, MD <i>Evolving Role of Effectiveness and Quality Performance Data</i>	_____	_____	_____
Marc Berger, MD <i>Challenges and Benefits of New CE Initiatives to Industry</i>	_____	_____	_____
Fadia Shaya, PhD, MPH <i>Role of CER, Coverage Determinations, and Value-Based Reimbursement</i>	_____	_____	_____
Sarah Garner, BPharm, MRPharmS, PhD <i>Comparative Effectiveness and Evidence-Based Decision-Making in the UK</i>	_____	_____	_____
Sean Tunis, MD, MSc <i>Collaborative Models for Priority Setting and Program Support</i>	_____	_____	_____
Bruce Marshall, MD <i>Case Study: Using a Registry for Multi-Stakeholder Needs</i>	_____	_____	_____
Nancy Dreyer, PhD, MPH Leanne Larson, MHA Michelle Bulliard, RN, BScN, MICR <i>Designing and Operating Registries</i>	_____	_____	_____
David Cooper, MD <i>Case Study: Maximizing Communications</i>	_____	_____	_____

Conference Feedback
 Please return to the conference registration desk or fax to: (617) 621-1620.

Please Circle:	High		Low		
Enough information prior to the conference?	5	4	3	2	1
Was the website informative?	5	4	3	2	1
Conference conducive to learning?	5	4	3	2	1
Was the registration process easy?	5	4	3	2	1
Was the staff knowledgeable and helpful?	5	4	3	2	1
Quality of the facilities:	5	4	3	2	1
Quality of the food:	5	4	3	2	1
Networking Reception:	5	4	3	2	1
Would you recommend the conference to a colleague?	5	4	3	2	1
Overall evaluation of the speakers and presentations:	5	4	3	2	1

What do you perceive to be the most pressing issues facing post-approval research in the next 6-12 months?

Who would you like to hear speak on these issues? (Please list their name, title and company)

Are there topics you felt should have been:

Added _____

Dropped _____

Additional Comments
